SCHEMBL339411

SCHEMBL339411

O=[C]CC1C2CC3CC(C2)CC1C3

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354701 0.74 HSD11B1 (0.39) HSD11B1CYP2C9
SCHEMBL9063591 0.70 ALDH1A1 (0.30)
SCHEMBL4507439 0.69 HSD11B1 (0.40) HSD11B1
SCHEMBL31226476 0.66 HSD11B1 (0.38) HSD11B1
SCHEMBL339975 0.64 MEN1 (0.40) CYP2C9
SCHEMBL159996 0.63 HSD11B1 (0.50) HSD11B1CYP2C9
SCHEMBL22462244 0.63 HSD11B1 (0.50) HSD11B1CYP2C9
SCHEMBL19017773 0.63 HSD11B1 (0.44) HSD11B1CYP2C9
SCHEMBL21650459 0.63 HSD11B1 (0.44) HSD11B1CYP2C9
SCHEMBL22483779 0.63 HSD11B1 (0.44) HSD11B1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119181-A1 Hydrophobically-modified protein compositions and methods BIOGEN IDEC INC. (US) 2005-06-02 US claimed
EP-1036092-B1 Hydrophobically-modified hedgehog protein compositions and methods BIOGEN INC (US) 2005-05-11 EP claimed
EP-1036092-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 2000-09-20 EP claimed
WO-1999028343-A9 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN INC (US) 1999-10-14 WO claimed
WO-1999028343-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 1999-06-10 WO claimed
EP-1646395-B1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY CURIS INC (US) 2014-11-05 EP disclosed
US-20130085096-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-04-04 US disclosed
US-20120269863-A1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY CURIS, INC. (US) 2012-10-25 US disclosed
US-20120238500-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO CURIS, INC. (US) 2012-09-20 US disclosed
US-8168178-B2 Methods and compositions for regulating lymphocyte activity CURIS, INC. (US) 2012-05-01 US disclosed
US-8097253-B2 Methods for inhibiting angiogenesis UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-01-17 US disclosed
EP-2359842-A1 Netrin-related compositions and uses University of Utah Research Foundation (US) 2011-08-24 EP disclosed
US-5888992-A PROTEASE INHIBITOR; VIRICIDE NARHEX LIMITED (HK) 1999-03-30 US disclosed
WO-1999010004-A2 REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO ONTOGENY, INC. (US) 1999-03-04 WO disclosed
US-5801274-A N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-09-01 US disclosed
US-5591891-A PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-01-07 US disclosed
EP-0717736-A4 POLAR-SUBSTITUTED HYDROCARBONS NARHEX LTD (HK) 1996-08-28 EP disclosed
EP-0717736-A1 POLAR-SUBSTITUTED HYDROCARBONS NARHEX LIMITED (HK) 1996-06-26 EP disclosed
WO-1995007269-A1 POLAR-SUBSTITUTED HYDROCARBONS NARHEX LIMITED (HK) 1995-03-16 WO disclosed
WO-1994017036-A1 S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238500-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO SHH, SMO, GLI1 HSD11B1 4419/4885CYP2C9 4884/4885
US-20130085096-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO SHH, FGF1, HGF HSD11B1 3964/4885CYP2C9 4877/4885
US-20120269863-A1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY SHH, ICOS, SMO HSD11B1 1713/4885CYP2C9 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.